New high performing assay product line yields consistent discrimination at lower levels
of detection required for clinical studies and patient stratification.
Billerica, Mass. — May 17, 2016 — Aushon BioSystems, a leading provider of high sensitivity assays, instrumentation and services for multiplex quantitative detection of protein biomarkers, today announced the launch of Ciraplex™ ULTRA Ultrasensitive Assays with multiplexing capabilities.
“We are excited about the recent collaboration with Pacific Biomarkers and believe the comparative results presented today clearly shows the superior performance characteristics of our new Ciraplex™ ULTRA product line”, said Susan Vogt, CEO of Aushon. “We are confident that our Cira™ platform is the most intuitive and easy-to-use ultrasensitive multiplex immunoassay platform on the market today.”
Ciraplex™ ULTRA Ultrasensitive Assays with femtogram/ml (fg/ml) levels of detection address multiple biomarkers in a wide range of therapeutic areas. These kits offer enhanced sensitivity and an extended dynamic range providing quantification below standard detection limits. As well, intuitive Cira™ software streamlines the data management process providing exceptional data control.
“Providing high performance multiplex immunoassays across a wide range of therapeutic areas is the goal of the Cira™ platform”, said Scott Van Arsdell, Ph.D., Vice President, Immunoassay Technology. “Our focus has been to create high sensitivity assays requiring less sample consumption while detecting very subtle differences in levels of low expression proteins.”
About Aushon BioSystems
Aushon BioSystems, Inc. is leading the way in protein biomarker discovery, development and analysis. Through the unique combination of proprietary microarray printing, extensive biomarker content and ease-of-use, the Cira™ immunoassay platform is serving leading pharmaceutical companies, contract research organizations and clinical reference laboratories worldwide. Our products are used for applications in preclinical and clinical biomarker research accelerating the evaluation of potential drug candidates and advancing the use of biomarker profiles in diagnostics. For more information go to: http://www.aushon.com
Billerica, Mass. — May 17, 2016 — Aushon BioSystems, a leading provider of high sensitivity assays, instrumentation and services for multiplex quantitative detection of protein biomarkers, today announced the launch of Ciraplex™ ULTRA Ultrasensitive Assays with multiplexing capabilities.
“We are excited about the recent collaboration with Pacific Biomarkers and believe the comparative results presented today clearly shows the superior performance characteristics of our new Ciraplex™ ULTRA product line”, said Susan Vogt, CEO of Aushon. “We are confident that our Cira™ platform is the most intuitive and easy-to-use ultrasensitive multiplex immunoassay platform on the market today.”
Ciraplex™ ULTRA Ultrasensitive Assays with femtogram/ml (fg/ml) levels of detection address multiple biomarkers in a wide range of therapeutic areas. These kits offer enhanced sensitivity and an extended dynamic range providing quantification below standard detection limits. As well, intuitive Cira™ software streamlines the data management process providing exceptional data control.
“Providing high performance multiplex immunoassays across a wide range of therapeutic areas is the goal of the Cira™ platform”, said Scott Van Arsdell, Ph.D., Vice President, Immunoassay Technology. “Our focus has been to create high sensitivity assays requiring less sample consumption while detecting very subtle differences in levels of low expression proteins.”
About Aushon BioSystems
Aushon BioSystems, Inc. is leading the way in protein biomarker discovery, development and analysis. Through the unique combination of proprietary microarray printing, extensive biomarker content and ease-of-use, the Cira™ immunoassay platform is serving leading pharmaceutical companies, contract research organizations and clinical reference laboratories worldwide. Our products are used for applications in preclinical and clinical biomarker research accelerating the evaluation of potential drug candidates and advancing the use of biomarker profiles in diagnostics. For more information go to: http://www.aushon.com
